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Background: Human rabies infection continues to be a significant public health burden globally, and is
occasionally imported to high income settings where the Milwaukee Protocol for intensive care management has
recently been employed, with limited success in improving survival. Access to molecular diagnostics, pre- and
post-mortem, and documentation of pathophysiological responses while using the Milwaukee protocol, can add
useful insights for the future of rabies management.
Case presentation: A 58-year-old British Asian woman was referred to a regional general hospital in the UK with
hydrophobia, anxiety and confusion nine weeks after receiving a dog bite in North West India. Nuchal skin biopsy,
saliva, and a skin biopsy from the site of the dog bite wound, taken on the day of admission, all demonstrated the
presence of rabies virus RNA. Within 48 hours sequence analysis of viral RNA confirmed the diagnosis and
demonstrated that the virus was a strain closely related to canine rabies viruses circulating in South Asia. Her
condition deteriorated rapidly with increased agitation and autonomic dysfunction. She was heavily sedated and
intubated on the day after admission, treated according to a modified Milwaukee protocol, and remained stable
until she developed heart block and profound acidosis and died on the eighth day. Analysis of autopsy samples
showed a complete absence of rabies neutralizing antibody in cerebrospinal fluid and serum, and corresponding
high levels of virus antigen and nucleic acid in brain and cerebrospinal fluid. Quantitative PCR showed virus was
also distributed widely in peripheral tissues despite mild or undetectable histopathological changes. Vagus nerve
branches in the heart showed neuritis, a probable Negri body but no demonstrable rabies antigen.
Conclusion: Rapid molecular diagnosis and strain typing is helpful in the management of human rabies infection.
Post-mortem findings such as vagal neuritis highlight clinically important effects on the cardiovascular system which
are typical for the clinical course of rabies in humans. Management guided by the Milwaukee protocol is feasible
within well-resourced intensive care units, but its role in improving outcome for canine-derived rabies remains
theoretical.
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Rabies continues to cause an estimated 24,000 -93,000 hu-
man deaths worldwide [1]. With an over-representation of
children among these cases, an estimated 1.74 (95% CI
0.75-2.93) million disability adjusted life years are lost an-
nually [1,2]. Rabies persists in reservoirs in wildlife and
domestic dogs putting humans and animals at risk. Glo-
bally, the overwhelming majority of confirmed human
cases are caused by rabies virus (RABV), one of twelve lys-
saviruses in the genus Lyssavirus, family Rhabdoviridae [3]
which is transmitted by contact with saliva from infected
animals by bite or scratch.
In areas free from terrestrial rabies, it has become ex-
tremely rare, with only four imported cases in the UK in
the last ten years [4-7].
Once clinical disease develops, rabies is invariably
fatal. The Milwaukee Protocol combination of therapies
was proposed to aid survival with the exemplar being an
unimmunised 15-year old girl with bat rabies in 2004
[8]. The supportive coma-induction, anti-excitatory and
antiviral therapies aim to minimise neurological disturb-
ance whilst the immune response confers sterilizing
immunity and virus is eliminated. Assessment of the
efficacy in subsequent attempts is confounded by vari-
ations in stage of presentation, exposure history and
treatment regimes [9-15]. Nonetheless, these attempts
re-enforce our understanding of rabies pathophysiology,
if there are to be further opportunities in building on
this initial success in developing an effective treatment
protocol. Here, we present a fatal case of human rabies
imported into the UK and discuss the rapid diagnosis,
virus distribution-associated pathology and our experience
with the Milwaukee Protocol.
Case presentation
A 58-year old woman, of South Asian ethnicity, was re-
ferred with painful paraesthesiae in the right forearm,
agitation, vomiting, and hydrophobia. During the 4 days
prior to admission she attended her general practitioner
(GP) and the local emergency department with painful
paraesthesiae in her right hand. On the second occasion
she was given tramadol; thereafter she began to vomit,
refused water, and appeared fearful and agitated. A fam-
ily member in India suggested that she may have rabies
in view of a history of a bite to the right forearm from
an ownerless puppy befriended by the patient during a
trip to a town near Ludhiana, India, 9 weeks previously.
The GP referred the patient to the local emergency de-
partment for further management (day 1). The case was
discussed with the Health Protection Agency; after an
initial blood sample was taken she received vaccine and
human rabies immunoglobulin and was transferred to
an isolation room in the University College London
Hospital intensive care unit.On arrival she demonstrated pronounced hydropho-
bia. Although the patient was able to suck on a moist
sponge, she gagged and became agitated when water
from the sponge dropped onto her bedclothes, or at
sight of a cup of water. Initial examination showed dehy-
dration, temperature of 37.9°C, heart rate 120 beats per
minute, blood pressure 171/90 mmHg; she was fully
conscious. There was no other abnormality on examin-
ation. Blood indices showed a mild neutrophilia, urea
7.9 mmol/L, creatinine 79 μmol/L, and normal C-reactive
protein. Saliva and skin biopsies from nuchal and bite sites
subsequently tested positive for lyssavirus ribonucleic
acid (RNA). Over the next few hours the patient devel-
oped episodes of extreme agitation despite escalating
doses of diazepam (2.5-7.5 mg iv - as frequently as every
hour); when one episode became violent she was anaes-
thetized with standard doses of fentanyl, midazolam,
propofol and rocuronium. The majority of elements of
the Milwaukee Protocol [15] were commenced. This in-
cluded drug-induced coma (propofol 200 mg/hr, fentanyl
200 mcg/hr and midazolam 20 mg/hr), neurotransmit-
ter substrate replenishment and antiviral therapy (aman-
tadine 200 mg bd). In addition she received nimodipine
60 mg 4 hourly, sapropoetin 200 mg bd, vitamin C
500 mg and coenzyme Q10 100 mg bd. Continuous elec-
troencephalogram (EEG) monitoring was adopted.
On day 3 she became hypotensive and was commenced
on noradrenaline (10-30 mcg/min to maintain a Mean
Arterial Pressure (MAP) >80 mmHg). Urine output was
responsive, however stroke volume and cardiac output
measurements by oesophageal Doppler were not respon-
sive, to fluid boluses. Ketamine sedation (45 mcg/kg/min)
was introduced. Adrenaline was added to maintain MAP.
By day 4, passive body warming was required for
hypothermia. Ventilatory requirements increased. Es-
calating doses of ketamine (60 mcg/kg/min), fentanyl
(300 mcg/hr) and propofol (70 mg/hr) were required to
maintain sedation. Antibiotics were commenced following
the suctioning of offensive sputum and evolving radio-
graphic infiltrates.
By day 5, progressive bilateral radiographic infiltrates
accompanied worsening hypercapnia. Polyuria with an
increasing serum Na+ was observed, and treated with
oesophageal Doppler-guided fluid optimisation, nasogas-
tric water and intravenous 5% dextrose. Glucose control
was required.
On day 6, paralysis (previously avoided due to risk of
masking seizures) was achieved with atracurium (10-
20 mg/hr) and nitric oxide introduced for intractable hyp-
oxaemia. Escalation of adrenaline (to 80 mcg/min) was
required for hypotension, cardiac output started to fall
and remained unresponsive. Pupils were dilated and dem-
onstrated sluggish reflex to light. Acidosis and multi-organ
failure ensued and haemofiltration was commenced.
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pine. As noradrenaline increased, hydrocortisone 50 mg
qds and fludrocortisone 100 mcg od were started.
On day 9, she developed a junctional rhythm with bra-
dycardic episodes requiring further sedation to ablate
the dys-autonomia, atropine boluses, isoprenaline infu-
sion and transvenous pacing.
On day 10, she developed refractory, profound lactic
acidosis. Management included 8.4% sodium bicarbonate
along with continuous veno-venous haemofiltration.
Persistent hypotension was treated with more adrenaline
(90 mcg/min) and noradrenaline (160 mcg/min) and
addition of argipressin (0.01 u/min). Antimicrobials were
escalated and suspected bowel ischaemia was treated sup-
portively as she was unfit for imaging or surgery. The
hypotension became refractory and temporary cessation




A lyssavirus differential TaqMan© reverse transcriptase
(RT)-PCR [16] was used to test for RABV RNA on
nucleic acids extracted from tissues. A hemi-nested RT-
PCR [17] was used to confirm results and generate prod-
uct for sequence analysis. The sequence derived was
compared to a range of regionally appropriate lyssavirus
sequences. Virus was isolated using a standard rabies tis-
sue culture infection test (RTCIT) using neuroblastoma
cells as described previously [18]. Viral antigen was de-
tected using the gold standard direct fluorescent antibody
test (FAT) with FITC-conjugated antibody (Fujirebio diag-
nostics) on acetone fixed brain smears, as described previ-
ously [18].
Differential TaqMan © RT-PCR [16] demonstrated
RABV RNA in all three initial samples (wound biopsy,
nuchal skin biopsy and saliva) within six hours of receipt
of samples on day 1. Wound biopsy and saliva were
strongly positive, with the nuchal biopsy showing lower
levels of RNA. A subsequent hemi-nested RT-PCR [17]
was negative on nuchal biopsy but positive on wound bi-
opsy and saliva. Subsequent saliva samples taken on day
1 were also positive by rabies TaqMan© and by nested
PCR with identical sequences to those derived from ini-
tial samples.
Phylogenetic analysis of partial nucleoprotein sequence
showed that the virus was a strain in the ‘arctic-like’
lineage 1 and most closely related to sequences derived
from dogs in Pakistan in 1979 and 1989, and in another
human case imported from India (RV61) (Figure 1).
Virus isolation, attempted on the first saliva sample,
was negative. Serum from day 1, before administration
of vaccine and immune globulin, was negative tested by
the fluorescent antibody virus neutralization test (FAVN)[18] for rabies antibodies, and negative for viral RNA by
real-time Taqman PCR (data not shown).
Autopsy
There was a terminal bronchopneumonia. The heart had
mild interstitial T-cell inflammation, and neuritis of
vagus nerve branches, including a possible Negri body
on Haematoxylin and eosin (H&E) stain (Figure 2), but
immunohistochemistry did not confirm this as rabies
antigen. The tongue (Figure 3a) and parotid gland also
had peri- and endoneural inflammation and ganglionitis.
The brain and meninges were grossly normal; there
was no cerebral swelling. Histologically, there was mild
encephalitis (T-cell infiltration, perivascular cuffing and
microgliosis), most prominent in temporal lobes. Neur-
onal rabies infection with abundant Negri bodies (round/
oval eosinophilic inclusions in the perikaryon) was present
in all parts of cerebrum and sub-tentorial brain tissue,
most prominently in the temporal lobe and hippocampus
(Figure 3b). No hypoxic-ischaemic neurone damage was
identified; only rare neurones were undergoing necrosis
with sattelitosis.
Postmortem samples and rabies identification
RABV antigen and nucleic acid were widely distributed
in central nervous system (CNS) and non-CNS tissues
post mortem (Figure 3). All brain regions were strongly
positive for RABV antigen using FAT; live virus was iso-
lated from brain and cerebrospinal fluid in tissue culture
at first passage. No neutralizing antibodies were detected
in CSF by FAVN. Although viral RNA was detected in
tongue, parotid salivary gland and a mouth swab taken
post mortem, live virus was not recovered from these
samples. Viral RNA was not detected in heart tissue.
Immunohistochemical demonstration of RABV antigen
in post-mortem samples from hippocampus, cerebellum,
medulla, tongue, parotid gland and myocardium was per-
formed as described previously [19]. Profuse antigen
was observed in the perikaryon and neuropil in all CNS
regions, including all cranial nerve roots identified
(Figure 3c). Abundant antigen was observed in auto-
nomic ganglia, muscle spindles and skeletal muscle fibres
in the tongue (Figure 3d). Limited amount of immunola-
belling was observed in nerve axons in the parotid gland.
No labelling was observed in lingual epithelium or parotid
acinary cells (data not shown).
Conclusion
This is the fifth case of rabies in the UK since 2000 and
highlights the need for better education of travellers and
clinicians on the risks of travel-related acquisition.
Rabies is a vaccine-preventable disease. UK imported
rabies cases, acquired through animal contact in rabies
endemic countries, have been uniformly fatal and were
Figure 1 Phylogenetic relationship between virus isolated in this case (Human ex-India 2012) and a global panel of rabies strains.
A Bayesian Markov–Chain-Monte-Carlo phylogenetic analysis was undertaken using BEAST (v1.8), with the most appropriate tree chosen using
Treeanotator and visualized using Figtree. Nodes with posterior probability values over 90% are shown.
Pathak et al. Virology Journal 2014, 11:63 Page 4 of 7
http://www.virologyj.com/content/11/1/63noted to have not received pre- or post-exposure
prophylaxis (PEP) [20]. Financial cost has been cited as a
reason for declining pre-exposure immunization [21]
and therefore, when appropriate, the advantages need
to be clearly communicated to justify the cost to the pa-
tient. The basis for poor post-exposure prophylaxis
remains unclear: a recent Geosentinel survey of 23,509
travellers found that 320 travellers sustained animal-
related injuries (mainly in Asia involving dogs) yet only
66% received PEP [22].Figure 2 Lymphocytic vagus neuritis in vagus nerve in the
heart, with one eosinophilic Negri-like body in the nerve
H&E 400×.This case illustrates the insidious and nonspecific symp-
toms that may precede rabies and reminds clinicians to
consider the diagnosis. Lack of awareness of potential ra-
bies exposure compounded with the nonspecific prodrome
that may precede neurological signs mean that delayed
clinical suspicion is frequent [23].
Phylogenetic analysis demonstrated that the virus iso-
lated from this patient was from a canine lineage of vi-
ruses thought to have evolved 500 years ago from strains
in Polar regions, and now a dominant strain in parts of
Asia [24,25]. The virus isolated here is very similar to
previous imported cases from India ten years previously
[6] and similar to cases in dogs in 1970s-1980s (Figure 1).
This implies that current strains are very similar to those
circulating in stable endemic independent cycles in the
region for the past 30 years. An average of only 57 rabies
cases have been reported in animals from the whole of
India annually since 2005 [26], and there is therefore
likely to be significant underreporting. This case illus-
trates the growing divide between countries where rabies
is endemic and underreported, and those where rabies is
extremely rare.
Until 2005, some form of prophylaxis was documented
in the handful of patients who survived clinical rabies
[27-31]. However, in 2004, in the absence of vaccination,
a 15-year-old girl with rabies, diagnosed on the basis of a
history of bat bite and anti-rabies antibodies in the CSF,
survived after the use of the Milwaukee Protocol [8]. The
protocol comprised therapeutic bundles based on re-
balancing an apparent rabies-induced tetrahyrobiopterin
Figure 3 Post-mortem histology demonstrating distribution of inflammation and rabies virus antigen in brain and muscle. a.
Ganglionitis in autonomic ganglia in the tongue. H&E 400×. b. Numerous Negri bodies (arrows) in neurons close to a perivascular cuff in brain
tissue (asterisk). H&E 400×. c. Immunohistochemical demonstration of rabies antigen in CNS (brown labelling). IHC 400×. d. Detection of rabies
antigen in muscle spindle (arrow) and skeletal muscle cells in the tongue (arrowheads). IHC 200×.
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and poor nitric oxidase activity [32] whilst the natural im-
mune response clears the virus, as reported in animal
models showing immune-mediated viral clearance from
the central nervous system and T-cell mediated neuronal
apoptosis [33-37].
The logistical complexities of adoption of the Milwaukee
Protocol are substantial, and this report provides additional
data on its lack of efficacy. Despite revisions to reduce ad-
verse reactions to component drugs [13,32,38], patients
treated by the Protocol and submitted on a central data-
base [39] number 43, of which only five (excluding the first
survivor) have been registered as survivors. Multiple
failed attempts have been described [9,11-13,40-42] in-
cluding the last UK imported case [7] but the potential
for efficacy has been debated due to case by case protocol
deviations. In the absence of animal trial data, the only
evidence for the protocol has emerged from individual
case review. Specific factors that appear relevant include:
therapy with rabies vaccine prior to onset of symptoms,
young age, lack of comorbidity, infection with bat rabies
variant, early evolution of neutralizing antibodies in serum
and CSF, and mild neurological disease [8,13,43-45]. Also
relevant is the immune response, as asymptomatic sero-
conversion and abortive infection have been described
[46-48]. In our case, the above positive prognostic factors
were absent. Furthermore, our case was treated withvaccine and immune globulin prior to institution of the
recommended protocol, which may have resulted in
delay in generation of the host immune response. As
in other cases, it was recommended initially (prior to dis-
ease confirmation) as part of the standardized post-
exposure protocol. This patient had no serum antibody on
presentation, and failed to develop detectable antibody
levels in CSF by day 8, which supports previous evidence
that lack of CSF antibody is a poor prognostic indicator. It
is unknown whether the patient would have developed an
effective immune response given sufficient time. We ac-
knowledge that, in future suspected cases, post exposure
prophylaxis should await results of diagnostic tests to give
the protocol optimum chance.
The actual mode of this patient’s death appears to have
been profound dysautonomia. Despite anticipating it, we
were ultimately unable to control it. Perhaps an earlier
and even more aggressive approach to dampen this
autonomic dysfunction may have changed the outcome,
but elements of the Milwaukee Protocol are at odds with
this therapeutic strategy. Other elements were just not
feasible on our ICU. Adoption of the Protocol remains
contentious. It may be that individualization of care in
future cases is possible with the identification of prog-
nostic biomarkers, and recent metabolomic studies on
the spinal fluid of 2 survivors versus 7 non-survivors
have proposed several biomarkers [49].
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through quantitative PCR in this case, demonstrate that
virus can be widely distributed. There was no detectable
RNA in the heart muscle, albeit from only one sampled
region (data not shown), however. virus replication cen-
tres (Negri bodies) in the cardiac vagus nerve were
detected histologically (Figure 3). Previously described
autopsy studies of cardiac tissue have shown the pres-
ence of rabies viral antigen deposits in the ganglia of three
cases, with concurrent ganglioneuritis and myocarditis
seen in two and one of the cases respectively - from which
it was inferred that centrifugal neuronal spread of the
rabies virus occurred with subsequent spread to the
myocardium [50]. Similarly, clinical and autopsy data in
this case support the spread of virus but do not conclu-
sively prove presence of virus in the heart. The antero-
grade axonal spread of virus is not well understood: it is
recognised that the virus will spread via the autonomic
nervous system to a wide range of organs including the
heart [51]; and that the latter is typical for the clinical
course of rabies in humans and leads to myocardial dys-
function and death.
In this case, the autopsy demonstrated the previ-
ously documented conundrum that death with brain
involvement occurs despite minimal encephalitis and
neuronal >loss [52]. However, the marked brainstem
involvement recently described in studies of viral antigen
distribution and magnetic resonance imaging (MRI) in
rabies patients [53-55] and implicated as potentially
relevant to centrally-mediated dysautonomia was not
seen here.
Consensus regarding the Milwaukee Protocol in pa-
tients with canine rabies will evolve as more outcomes
are published. In the interim, the emphasis of manage-
ment is based on timely diagnosis to optimise supportive
care. The prompt availability of the sequence and phylo-
genetic analysis of the virus also aided clarification of
the source as this was not initially clear. Much can be
learnt from the promptness of confirmation of diagnosis
in this case, as well as the efficient and daily coordination
of information between specialist and referring hospitals,
public health authorities and national experts which was
crucial in this patient’s care and minimization of onward
transmission. This highlights the benefit of discussion
on a daily basis by relevant experts and fully encom-
passes the ‘One Health’ agenda [56] for rare imported
human infectious diseases.
Consent
Written informed consent was obtained from the pa-
tient’s next of kin for publication of this Case Report
and any accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.Abbreviations
RNA: Ribonucleic acid; CSF: Cerebrospinal fluid; PCR: Polymerase chain
reaction; RABV: Rabies virus; GP: General practitioner;
EEG: Electroencephalogram; MAP: Mean arterial pressure; RT-PCR: Reverse
transcriptase polymerase chain reaction; RTCIT: Rabies tissue culture infection
test; FAT: Fluorescent antibody test; FITC: Flourescein isothyanate; PEP:
Post-exposure prophylaxis; H&E: Haematoxylin and eosin; CNS: Central
nervous system; FAVN: Fluorescent antibody virus neutralization test.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
SmP, DH, MB and ARF drafted the manuscript. DH, AN, EW & ARF carried out
the molecular virology studies, participated in the sequence alignment and
drafted the virological sections of the manuscript. MB, EN, SQ, SmP, SaP, DH,
ARF, DW and DB researched the literature, co-ordinated the management of
the case, discussed the scientific issues around management and helped to
draft the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The UK National Reference Laboratory for rabies at AHVLA is funded by the
Department for Environment, Food and Rural Affairs (Defra) under grant
SV3500. The authors wish to acknowledge Denise Marston and Dr Richard
Ellis (AHVLA) for sequence analysis; Dr Daniel Hicks (AHVLA Pathology
Department) for technical support; Dr Emma Crawley-Boevey, Dilys Morgan,
Kevin Brown, Hilary Kirkbride and colleagues at Public Health England for
their contribution to the public health response; and Dr R Willoughby
(Wisconsin, USA) for his helpful advice during management of the case.
Author details
1Hospital for Tropical Diseases, Virology and Intensive Care Units, University
College Hospitals NHS Foundation Trust, London, UK. 2Animal Health and
Veterinary Laboratories Agency (AHVLA), Wildlife Zoonoses and Vector-borne
Diseases Research Group, Department of Virology, Weybridge, Surrey KT15
3NB, UK. 3Public Health England (formally Health Protection Agency),
London, UK. 4Department of Clinical Infection, Microbiology and
Immunology, University of Liverpool, Liverpool L3 5TQ, UK. 5London School
of Hygiene and Tropical Medicine, London, UK. 6Department of
Histopathology, St Thomas’ Hospital, London, UK.
Received: 24 March 2014 Accepted: 24 March 2014
Published: 7 April 2014
References
1. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME,
Shaw A, Zinsstag J, Meslin FX: Re-evaluating the burden of rabies in Africa
and Asia. Bull World Health Organ 2005, 83:360–368.
2. Mallewa M, Fooks AR, Banda D, Chikungwa P, Mankhambo L, Molyneux E,
Molyneux ME, Solomon T: Rabies encephalitis in malaria-endemic area,
Malawi, Africa. Emerg Infect Dis 2007, 13:136–139.
3. Banyard AC, Hayman D, Johnson N, McElhinney L, Fooks AR: Bats and
lyssaviruses. Adv Virus Res 2011, 79:239–289.
4. Johnson N, Lipscomb DW, Stott R, Rao GG, Mansfield K, Smith J, McElhinney
L, Fooks AR: Investigation of a human case of rabies in the United
Kingdom. J Clin Virol 2002, 25:351–356.
5. Smith J, McElhinney L, Parsons G, Brink N, Doherty T, Agranoff D, Miranda
ME, Fooks AR: Case report: rapid ante-mortem diagnosis of a human case
of rabies imported into the UK from the Philippines. J Med Virol 2003,
69:150–155.
6. Solomon T, Marston D, Mallewa M, Felton T, Shaw S, McElhinney LM, Das K,
Mansfield K, Wainwright J, Kwong GN, Fooks AR: Paralytic rabies after a
two week holiday in India. BMJ 2005, 331:501–503.
7. Hunter M, Johnson N, Hedderwick S, McCaughey C, Lowry K, McConville J,
Herron B, McQuaid S, Marston D, Goddard T, Harkess G, Goharriz H, Voller K,
Solomon T, Willoughby RE, Fooks AR: Immunovirological correlates in
human rabies treated with therapeutic coma. J Med Virol 2010,
82:1255–1265.
8. Willoughby RE Jr, Tieves KS, Hoffman GM, Ghanayem NS, Amlie-Lefond CM,
Schwabe MJ, Chusid MJ, Rupprecht CE: Survival after treatment of rabies
with induction of coma. N Engl J Med 2005, 352:2508–2514.
Pathak et al. Virology Journal 2014, 11:63 Page 7 of 7
http://www.virologyj.com/content/11/1/639. Hemachudha T, Sunsaneewitayakul B, Desudchit T, Suankratay C, Sittipunt C,
Wacharapluesadee S, Khawplod P, Wilde H, Jackson AC: Failure of
therapeutic coma and ketamine for therapy of human rabies. J Neurovirol
2006, 12(5):407–409.
10. Centers for Disease, Control Prevention: Human rabies – Indiana and
California, 2006. MMWR Morb Mortal Wkly Rep 2007, 56:361–5.
11. Schmiedel S, Panning M, Lohse A, Kreymann KG, Gerloff C, Burchard G,
Drosten C: Case report on fatal human rabies infection in Hamburg,
Germany, March 2007. Euro Surveill 2007, 12:E070531–5.
12. McDermid RC, Saxinger L, Lee B, Johnstone J, Gibney RTN, Johnson M,
Bagshaw SM: Human rabies encephalitis following bat exposure: failure
of therapeutic coma. CMAJ 2008, 178:557–561.
13. Rubin J, David D, Willoughby RE Jr, Rupprecht CE, Garcia C, Guarda
DC, Zohar Z, Stamler A: Applying the Milwaukee Protocol to treat
canine rabies in Equatorial Guinea. Scand J Infect Dis 2009,
41:372–375.
14. Aramburo A, Willoughby RE, Bollen AW, Glaser CA, Hsieh CJ, Davis SL,
Martin KW, Roy-Burman A: Failure of the Milwaukee Protocol in a child
with rabies. Clin Infect Dis 2011, 53:572–574.
15. The Medical College of Wisconsin: Care of rabies version 3.1 Last updated
June 22, 2009. [http://www.cdc.gov.tw/uploads/files/201208/eea0e9a9-
7ce7-42b6-acc4-22b189c0d87f.pdf]
16. Wakeley PR, Johnson N, McElhinney LM, Marston D, Sawyer J, Fooks AR:
Development of a real-time, TaqMan reverse transcription-PCR assay for
detection and differentiation of lyssavirus genotypes 1, 5, and 6. J Clin
Microbiol 2005, 43:2786–2792.
17. Heaton PR, Johnstone P, McElhinney LM, Cowley R, O’Sullivan E, Whitby JE:
Heminested PCR assay for detection of six genotypes of rabies and
rabies-related viruses. J Clin Microbiol 1997, 35:2762–2766.
18. OIE World Organisation for Animal Health: Manual of diagnostic tests and
vaccines for terrestrial animals (mammals, birds and bees). 2012 [http://
www.oie.int/manual_of_diagnostic_tests_and_vaccines_for_terrestial_animals]
19. Hicks DJ, Nunez A, Healy DM, Brookes SM, Johnson N, Fooks AR:
Comparative pathological study of the murine brain after experimental
infection with classical rabies virus and European bat lyssaviruses.
J Comp Pathol 2009, 140:113–126.
20. Johnson N, Freuling C, Horton D, Mueller T, Fooks AR: Imported rabies,
European Union and Switzerland, 2001–2010. Emerg Infect Dis 2011,
17:753–754.
21. Fooks AR, Johnson N, Brookes SM, Parsons G, McElhinney LM: Risk factors
associated with travel to rabies endemic countries. J Appl Microbiol 2003,
94:31S–36S.
22. Gautret P, Schwartz E, Shaw M, Soula G, Gazin P, Delmont J, Parola P, Soavi
MJ, Matchett E, Brown G, Torresi J: Animal-associated injuries and related
diseases among returned travellers: a review of the GeoSentinel
Surveillance Network. Vaccine 2007, 25:2656–2663.
23. Centers for Disease, Control Prevention: Imported human rabies -New
Jersey, 2011. Morb Mortal Wkly Rep 2012, 60:1734–1736.
24. Nadin-Davis SA, Turner G, Paul JP, Madhusudana SN, Wandeler AI:
Emergence of arctic-like rabies lineage in India. Emerg Infect Dis 2007,
13:111–116.
25. Kuzmin IV, Hughes GJ, Botvinkin AD, Gribencha SG, Rupprecht CE: Arctic
and Arctic-like rabies viruses: distribution, phylogeny and evolutionary
history. Epidemiol Infect 2008, 136:509–519.
26. World Animal Health Information Database (WAHID) Interface. [http://www.
oie.int/wahis_2/public/wahid.php/Wahidhome/Home]
27. Hattwick MA, Weis TT, Stechschulte CJ, Baer GM, Gregg MB: Recovery from
rabies. A case report. Ann Intern Med 1972, 76:931–942.
28. Porras C, Barboza JJ, Fuenzalida E, Adaros HL, Oviedo AM, Furst J: Recovery
from rabies in man. Ann Intern Med 1976, 85:44–58.
29. Tillotson JR, Axelrod D, Lyman DO: Rabies in a laboratory worker;
New York. Morb Mortal Wkly Rep 1977, 26:183–184.
30. Alvarez L, Fajardo R, Lopez E, Pedroza R, Hemachudha T, Kamolvarin N,
Cortes G, Baer GM: Partial recovery from rabies in a nine-year-old boy.
Pediatr Infect Dis J 1994, 13:1154–1155.
31. Jackson AC: Rabies: new insights into pathogenesis and treatment.
Curr Opin Neurol 2006, 19:267–270.
32. Willoughby RE, Opladen T, Maier T, Rhead W, Schmiedel S, Hoyer J, Drosten
C, Rupprecht CE, Hyland K, Hoffmann GF: Tetrahydrobiopterin deficiency
in human rabies. J Inherit Metab Dis 2009, 32:65–72.33. Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B:
Collaboration of antibody and inflammation in clearance of rabies virus
from the central nervous system. J Virol 1998, 72:3711–3719.
34. Galelli A, Baloul L, Lafon M: Abortive rabies virus central nervous infection
is controlled by T lymphocyte local recruitment and induction of
apoptosis. J Neurovirol 2000, 6:359–372.
35. Rubin RH, Sullivan L, Summers R, Gregg MB, Sikes RK: A case of human
rabies in Kansas: epidemiologic, clinical, and laboratory considerations.
J Infect Dis 1970, 122:318–322.
36. Emmons RW, Leonard LL, DeGenaro F Jr, Protas ES, Bazeley PL, Giammona
ST, Sturckow K: A case of human rabies with prolonged survival.
Intervirology 1973, 1:60–72.
37. Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM: NK cells as effectors of
acquired immune responses: effector CD4(+) T cell-dependent activation
of NK cells following vaccination. J Immunol 2010, 185:2808–2818.
38. Willoughby RE Jr: A cure for rabies? Sci Am 2007, 296:88–95.
39. Children’s Hospital of Wisconsin: Rabies Registry Home Page. [http://www.
mcw.edu/Pediatrics/InfectiousDiseases/PatientCare/Rabies.htm]
40. Centers for Disease, Control Prevention: Human rabies–Alberta, Canada,
2007. MMWR Morb Mortal Wkly Rep 2008, 57:197–200.
41. Jackson AC: Therapy of human rabies. Adv Virus Res 2011, 79:365–375.
42. Jackson AC: Current and future approaches to the therapy of human
rabies. Antiviral Res 2013, 99:61–67.
43. Warrell MJ, Warrell DA: Rabies and other lyssavirus diseases. Lancet 2004,
363:959–969.
44. Phares TW, Kean RB, Mikheeva T, Hooper DC: Regional differences in
blood–brain barrier permeability changes and inflammation in the
apathogenic clearance of virus from the central nervous system.
J Immunol 2006, 176:7666–7675.
45. Dietzschold B, Li J, Faber M, Schnell M: Concepts in the pathogenesis of
rabies. Future Virol 2008, 3:481–490.
46. Gilbert AT, Petersen BW, Recuenco S, Niezgoda M, Gomez J, Alberto
Laguna-Torres V, Rupprecht C: Evidence of rabies virus exposure among
humans in the Peruvian Amazon. Am J Trop Med Hyg 2012, 87:206–215.
47. Maier T, Schwarting A, Mauer D, Ross RS, Martens A, Kliem V, Wahl J,
Panning M, Baumgarte S, Mueller T, Pfefferle S, Ebel H, Schmidt J, Tenner-Racz
K, Racz P, Schmid M, Struber M, Wolters B, Gotthardt D, Bitz F, Frisch L, Pfeiffer
N, Fickenscher H, Sauer P, Rupprecht CE, Roggendorf M, Haverich A, Galle P,
Hoyer J, Drosten C: Management and outcomes after multiple corneal and
solid organ transplantations from a donor infected with rabies virus.
Clin Infect Dis 2010, 50:1112–1119.
48. Centers for Disease, Control Prevention: Presumptive abortive human
rabies - Texas, 2009. Morb Mortal Wkly Rep 2010, 59:185–190.
49. O’Sullivan A, Willoughby RE, Mishchuk D, Alcarraz B, Cabezas-Sanchez C,
Condori RE, David D, Encarnacion R, Fatteh N, Fernandez J, Franka R,
Hedderwick S, McCaughey C, Ondrush J, Paez-Martinez A, Rupprecht C,
Velasco-Villa A, Slupsky CM: Metabolomics of cerebrospinal fluid from
humans treated for rabies. J Proteome Res 2013, 12:481–90.
50. Metze K, Feiden W: Rabies virus nucleoprotein in the heart. N Engl J Med
1991, 324:1814–5.
51. Feiden W: Neuritis cordis and myocarditis in rabies. Pathologe 2013,
34:165–169.
52. Mrak RE, Young L: Rabies encephalitis in humans: pathology,
pathogenesis and pathophysiology. J Neuropathol Exp Neurol 1994,
53:1–10.
53. Pleasure SJ, Fischbein NJ: Correlation of clinical and neuroimaging
findings in a case of rabies encephalitis. Arch Neurol 2000, 57:1765–9.
54. Laothamatas J, Hemachudha T, Mitrabhakdi E, Wannakrairot P,
Tulayadaechanont S: MR imaging in human rabies. AJNR Am Neuroradiol
2003, 24:1102–9.
55. Hemachudha T, Ugolini G, Wacharapluesadee S, Sungkarat W, Shuangshoti
S, Laothamatas J: Human rabies: neuropathogenesis, diagnosis and
management. Lancet Neurol 2013, 12:498–513.
56. Fooks AR: Rabies - the need for a 'one medicine' approach. Vet Rec 2007,
161:289–290.
doi:10.1186/1743-422X-11-63
Cite this article as: Pathak et al.: Diagnosis, management and
post-mortem findings of a human case of rabies imported into the
United Kingdom from India: a case report. Virology Journal 2014 11:63.
